The Golden Ticket

UTR Sports Announces Franklin Sports as Official Ball of Pickleball Amateur Series

Retrieved on: 
Thursday, February 22, 2024

Palo Alto, CA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- UTR Sports (formerly Universal Tennis) is announcing Franklin Sports , a leading manufacturer and retailer in the sporting goods industry, as the official pickleball ball partner of UTR Sports and the UTR Sports Pickleball Amateur Series .

Key Points: 
  • Palo Alto, CA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- UTR Sports (formerly Universal Tennis) is announcing Franklin Sports , a leading manufacturer and retailer in the sporting goods industry, as the official pickleball ball partner of UTR Sports and the UTR Sports Pickleball Amateur Series .
  • The UTR Sports Pickleball Amateur Series is a new year-round series of pickleball tournaments held across the United States throughout 2024.
  • Two of the Pickleball Amateur Series events are USA Pickleball Golden Ticket qualifiers, where players have a chance to earn the exclusive opportunity to pre-register for the 2024 USA Pickleball National Championships.
  • "Franklin Sports is thrilled to become the official ball partner of UTR Sports,” said Adam Franklin, President of Franklin Sports.

Dollywood’s Big Bear Mountain Now Open, Sending Riders to Search for “Big Bear”

Retrieved on: 
Friday, May 12, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230512005051/en/
    Dollywood's Big Bear Mountain, the theme park's longest roller coaster, officially opened on Friday, May 12.
  • Dollywood guests are invited to assist Wildwood Grove’s resident wilderness explorer, Ned Oakley, in his quest to find Big Bear.
  • In addition to the opening of Big Bear Mountain, Dollywood’s HeartSong Lodge & Resort is slated to open this November.
  • For more information about Big Bear Mountain, Dollywood’s HeartSong Lodge & Resort, and the 2023 operating season, please visit dollywood.com .

Albatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation

Retrieved on: 
Tuesday, April 25, 2023

The company also received the first Golden Ticket prize from Amgen in Singapore, recognizing the viability of its science and business plan.

Key Points: 
  • The company also received the first Golden Ticket prize from Amgen in Singapore, recognizing the viability of its science and business plan.
  • Cancer that has metastasized, spreading to other parts of the body, is notoriously difficult to treat and accounts for most cancer deaths.
  • Albatroz has secured exclusive rights on a highly specific and novel target that blocks tumor growth and recurrence, including a range of therapeutic antibodies that inhibit this target.
  • Activation of the target occurs specifically in tumors and arthritic synovial membranes, connective tissue that lines the joint capsule.

ONO PHARMA USA Announces 2023 Golden Ticket Competition in Partnership with LabCentral and MBC BioLabs

Retrieved on: 
Tuesday, April 18, 2023

CAMBRIDGE, Mass., April 18, 2023 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco, to award each organization one Golden Ticket for an innovative life sciences startup company.

Key Points: 
  • CAMBRIDGE, Mass., April 18, 2023 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco, to award each organization one Golden Ticket for an innovative life sciences startup company.
  • The competition is sponsored by ONO PHARMA USA's parent company, Ono Pharmaceutical Co., Ltd. (ONO), and applications will be received through May 2023.
  • The Golden Ticket awards provide promising early-stage R&D companies lab space and mentorship, two components vital to the success of nascent life science businesses.
  • "As longtime believers in open innovation and the power of partnerships, we are excited once again to offer this Golden Ticket competition in collaboration with LabCentral and MBC BioLabs," said Kunihiko Ito, President and CEO of ONO PHARMA USA.

Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal

Retrieved on: 
Wednesday, March 1, 2023

The financing will be used to advance Thymmune’s lead product THY-100 into preclinical studies in immune system disorders caused by thymic deficiencies (such as children born without a thymus), which result in a lack of functional T cells.

Key Points: 
  • The financing will be used to advance Thymmune’s lead product THY-100 into preclinical studies in immune system disorders caused by thymic deficiencies (such as children born without a thymus), which result in a lack of functional T cells.
  • The funding will also be used to develop its thymic cell engineering platform and expand into additional indications across areas of unmet clinical need in immunology.
  • The thymus is a critical organ in the immune system that regulates and develops T cells, which are essential for fighting infection and disease, along with mounting effective responses to vaccines.
  • Thymmune has also received funding via Wellcome Leap’s inaugural HOPE program, along with an NIH/NIAID Fast-Track SBIR.

BOLDEN THERAPEUTICS RECEIVES $406,466 SBIR GRANT FROM THE NATIONAL INSTITUTE ON AGING TO SUPPORT DEVELOPMENT OF ANTISENSE OLIGONUCLEOTIDES TO PROMOTE NEUROGENESIS

Retrieved on: 
Friday, September 16, 2022

"This REDI award will provide important support to advance our antisense oligonucleotide program and further establish proof of concept in Alzheimer's disease models," said Johnny Page, Co-Founder and CEO of Bolden Therapeutics.

Key Points: 
  • "This REDI award will provide important support to advance our antisense oligonucleotide program and further establish proof of concept in Alzheimer's disease models," said Johnny Page, Co-Founder and CEO of Bolden Therapeutics.
  • The REDI grant mechanism provides bio-entrepreneurship training to facilitate more diverse career options for early-career scientists working in the fields of aging and aging-related diseases, such as Alzheimer's disease.
  • "I am very excited about this opportunity to advance my entrepreneurial skills," said Anne Valat, Ph.D., Principal Scientist of Bolden Therapeutics and Principal Investigator of the REDI SBIR grant.
  • The SBIR award is entitled 'Entrepreneurial development award for a novel Alzheimer's disease therapeutic' and will support further investigation of antisense candidates in vivo.

BOLDEN THERAPEUTICS RECEIVES $497,500 SBIR GRANT FROM THE NATIONAL INSTITUTE ON AGING TO SUPPORT DEVELOPMENT OF ANTISENSE OLIGONUCLEOTIDES TO PROMOTE NEUROGENESIS

Retrieved on: 
Wednesday, June 29, 2022

CAMBRIDGE, Mass., June 29, 2022 /PRNewswire/ -- Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced being awarded a Small Business Innovative Research (SBIR) grant for $497,500 from the National Institute on Aging (NIA) of the National Institutes of Health.

Key Points: 
  • CAMBRIDGE, Mass., June 29, 2022 /PRNewswire/ -- Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced being awarded a Small Business Innovative Research (SBIR) grant for $497,500 from the National Institute on Aging (NIA) of the National Institutes of Health.
  • "This SBIR award from the NIA will further our development of our exon-skipping antisense oligonucleotide (ASO) candidates to modulate the expression of a genetically-validated target for increasing neurogenesis," said Johnny Page, Co-Founder and CEO of Bolden Therapeutics.
  • "With the support of these funds, we will be able to advance our ASO candidates in mouse models of Alzheimer's disease," said Anne Valat, Ph.D., Principal Scientist of Bolden Therapeutics and Principal Investigator of the SBIR grant.
  • The company is developing antisense oligonucleotides to modulate this genetically-validated target.

LG Chem Life Sciences Innovation Center and LabCentral Announce the 2022 Golden Ticket Winner – Rubik Therapeutics

Retrieved on: 
Wednesday, May 25, 2022

Today, LG Chem Life Sciences Innovation Center announced that it has selected Rubik Therapeutics as the winner of their 2022 LabCentral Golden Ticket Program.

Key Points: 
  • Today, LG Chem Life Sciences Innovation Center announced that it has selected Rubik Therapeutics as the winner of their 2022 LabCentral Golden Ticket Program.
  • View the full release here: https://www.businesswire.com/news/home/20220525005287/en/
    LG Chem Life Sciences Innovation Center presents 2022 LabCentral Golden Ticket to Rubik Therapeutics.
  • (Photo: Business Wire)
    As a LabCentral sponsor, LG Chem Life Sciences Innovation Center can select a qualifying startup company each year to take up residence in LabCentrals Kendall Square facility through use of the Golden Ticket.
  • This year is the third year of LG Chem Life Sciences Innovation Centers Golden Ticket Program and it is designed to assist high-potential and innovative early-stage life science and biotech companies.

Bakar Labs and the Cystic Fibrosis Foundation Support Entrepreneurs to Develop New Genetic Therapies for CF

Retrieved on: 
Monday, April 18, 2022

Up to three potential winners will be provided lab space and facilities at Bakar Labs.

Key Points: 
  • Up to three potential winners will be provided lab space and facilities at Bakar Labs.
  • "Our double bottom line at Bakar Labs emphasizes public good on an equal basis with the potential for profit."
  • "Collaborating with the CF Foundation creates an extraordinary opportunity," said Gino Segr, PhD, managing director of Bakar Labs.
  • The CF Foundation has achieved global admiration for its support of disease-related research efforts, not only by scientists in academic labs but by entrepreneurs in startup companies.

LabCentral Releases 2021 Impact Report: Companies Raised $6.03 Billion in Funding and Launched 80 New Clinical Trials

Retrieved on: 
Thursday, April 7, 2022

CAMBRIDGE, Mass., April 7, 2022 /PRNewswire/ --  LabCentral, a network of premier laboratory and co-working facilities for high-potential biotech start-ups, today announced its annual Impact Report detailing the influence of its 245 resident and 117 alumni companies on the local and national life sciences and biotech industry. The impact was measured in terms of clinical trials, investment, job creation as well as LabCentral's expanded facilities and programs from the past year. The 2021 Impact Report is available to download from LabCentral's website, in addition to reports from previous years.

Key Points: 
  • Key statistics from the LabCentral 2021 Impact Report include:
    Clinical Research Highlighting the success of its resident and alumni companies to quickly move from idea to research to clinical trials, LabCentral had more than 31 companies researching 24 unique indications with over 80 different technologies in clinical trials last year.
  • Since its founding in 2013, LabCentral companies have dosed 6,917 participants as part of clinical trials.
  • Funding LabCentral companies have raised a total of $16.9 billion in funding since 2013.
  • In 2021 alone, LabCentral resident and alumni companies secured $6.03 billion in funding from all sources.